Scott, Andrew C.
Dündar, Friederike
Zumbo, Paul
Chandran, Smita S.
Klebanoff, Christopher A.
Shakiba, Mojdeh
Trivedi, Prerak
Menocal, Laura
Appleby, Heather
Camara, Steven
Zamarin, Dmitriy
Walther, Tyler
Snyder, Alexandra
Femia, Matthew R.
Comen, Elizabeth A.
Wen, Hannah Y.
Hellmann, Matthew D.
Anandasabapathy, Niroshana
Liu, Yong
Altorki, Nasser K.
Lauer, Peter
Levy, Olivier
Glickman, Michael S.
Kaye, Jonathan
Betel, Doron
Philip, Mary
Schietinger, Andrea
Article History
Received: 18 May 2018
Accepted: 4 June 2019
First Online: 17 June 2019
Competing interests
: C.A.K. is a consultant and/or advisor to Aleta Biotherapeutics, Bellicum Pharmaceuticals, Bristol-Meyers Squibb, Cell Design Labs, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics and Rxi Therapeutics. C.A.K. receives research funding unrelated to this work from Kite/Gilead. M.D.H. has received research funding from Bristol-Myers Squibb; is paid as a consultant to Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Janssen, Nektar, Syndax, Mirati, and Shattuck Labs; has received travel support/honoraria from AstraZeneca and BMS; a patent has been filed by MSK related to the use of tumour mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. A. Snyder is a current employee and owns stock in Merck. D.Z. reports grants from Merck, and consulting fees from Merck, Synlogic Therapeutics, Trieza Therapeutics, and Tesaro. D.Z. owns a patent concerning the use of Newcastle Disease Virus for cancer therapy. M.S.G. is a paid consultant to Vedanta Biosciences and Takeda for work unrelated to this study. E.A.C. is a consultant to Pfizer, Novartis, Genentech/Roche, Cota, Heron Therapeutics, and Bristol-Myers Squibb; has received travel support/honoraria from Pfizer and Novartis; and receives research funding from Genentech/Roche unrelated to this work.